The sequence of all novel multilocus sequence type alleles are available from the GenBank database (accession number(s) MG675061-MG675064). Details of novel multilocus sequence types is also available at the Streptococcus pneumoniae MLST database (<https://pubmlst.org/spneumoniae/>).

Introduction {#sec001}
============

Asymptomatic colonization of the nasopharynx is considered a precursor for clinical pneumococcal disease. Levels of colonization are higher in children than adults and certain groups of patients could be at increased risk of developing pneumococcal infection \[[@pone.0206305.ref001]--[@pone.0206305.ref003]\]. Patients with tracheostomies have pneumococcal colonization of their lower respiratory tract; however, little is known about the strains colonizing these patients \[[@pone.0206305.ref004], [@pone.0206305.ref005]\]. A study published in 1979 examined pneumococcal colonization of 27 children (mean age of 8.5 years) biweekly over a one year period \[[@pone.0206305.ref005]\]. Pneumococci were isolated from 22.5% of the 444 samples taken; although, 22 of those isolates were from patients with active pneumonia. A more recent study of tracheostomy patients, both adults and children, at a long-term care facility revealed 17% of cultures were positive for pneumococci \[[@pone.0206305.ref004]\]. This study also defined the serotypes of endotracheal isolates. They did not differentiate the isolates from adult and pediatric patients, but the serotypes of the isolates were 23F, 19F, 17F, 15A, 6A and some non-typeable.

*Streptococcus pneumoniae* is a diverse species, as demonstrated by the \>90 serotypes \[[@pone.0206305.ref006]\]. While the 7-valent conjugate vaccine (PCV7) reduced invasive disease and colonization by vaccine types, some other serotypes increased in prevalence \[[@pone.0206305.ref007], [@pone.0206305.ref008]\]. Introduction of PCV13 further reduced pneumococcal disease, but recent reports indicate similar increases in colonization and disease due to some non-vaccine serotypes \[[@pone.0206305.ref009], [@pone.0206305.ref010], [@pone.0206305.ref011]\].

Although strains have different propensities to cause disease, studying strains colonizing patients with underlying conditions may identify pneumococcal lineages likely to cause disease. Isolates colonizing paediatric patients with tracheostomies have rarely been evaluated. Thus, we compared the serotypes, susceptibility to penicillin, and genetic background of pneumococci colonizing the lower respiratory tract of children with tracheostomies and a convenience sample of children intubated due to acute non-pneumococcal illness.

Materials and methods {#sec002}
=====================

Medical records at Nationwide Children's Hospital, Columbus, Ohio from January 2013 to December 2014 were reviewed following Institutional Review Board (IRB) approval (IRB16-00812). Given that the study was reviewed as Risk Level 1, no greater than minimal risk, and involved retrospective chart review, the IRB waived the requirement for informed consent. We identified tracheostomy patients from which a pneumococcal isolate was recovered from deep tracheal aspirates. Deep tracheal aspirates were collected by trained medical staff and respiratory therapists, using sterile technique and standard airway precautions, thus minimizing the risk of contamination with upper respiratory tract flora to the extent possible. A single isolate from each patient was used. If the same patient was hospitalized multiple times during the study period, the first pneumococcal isolate obtained was used in the study. No individual had documented pneumococcal disease within the prior year. This resulted in 27 isolates for use in the study. For comparison we used a convenience sample of the 42 isolates from deep tracheal aspirates patients intubated for acute conditions and cultured within 24 hours of admission obtained over the same study period. The majority of patients were children; however, but a few older than 18 years of age were also treated at our hospital due to their pre-existing chronic conditions. Whether there were any significant differences between the patient populations were assessed using a two-tailed chi-squared test with Yate's correction (P ≤ 0.05). The exception was for age, where statistical significance of differences was assessed by a two-tailed Student's *t* test.

Samples were cultured using conventional media including sheep blood, chocolate and MacConkey agars with and plates incubated at 37°C in 5% CO~2~. Pneumococci were identified by optochin susceptibility, latex agglutination or Vitek GP Cards (bioMerieux). Antimicrobial susceptibilities were performed using Etest strips (bioMerieux) with established breakpoints \[[@pone.0206305.ref012]\]. Isolates were recovered from frozen stocks and grown for DNA preparation using previously described methodology \[[@pone.0206305.ref013]\]. Multi-locus Sequence Typing (MLST) was used to define the genetic background of isolates (<http://pubmlst.org/spneumoniae/>). Genetic relatedness and clonal complexes, named for the predicted founder, were inferred using goeBURST available in PHYLOViZ 2.0. Novel alleles are available in GenBank (accession numbers MG675061-MG675064) and added to the pneumococcal MLST database.

Serotypes were assigned using multiplex PCR \[[@pone.0206305.ref014]\]. The serotype of multiplex-negative isolates was determined by the Quellung reaction (Statens Serum Institute). Non-typeable isolates were screened for genes that replace the capsule locus in some cases, *pspK* \[[@pone.0206305.ref015]\], *aliC* (*aliC*F AGATGCCAAATGGTTCACGC and *aliC*R GCGCTTTGTTATACCTAGATGTTTC) and *ali*D \[[@pone.0206305.ref016]\]. A two-tailed chi-squared test with Yate's correction was used to identify any significant differences (P ≤ 0.05) between the two groups of isolates.

Results {#sec003}
=======

All tracheostomy patients had underlying conditions associated with respiratory failure requiring chronic ventilation including Trisomy 18, DiGeorge syndrome, muscular dystrophy, traumatic injuries with spinal cord transection, severe cerebral palsy, congenital tracheal abnormalities and cystic lymphangiomas ([S1 Table](#pone.0206305.s001){ref-type="supplementary-material"}). The convenience sample included 15 previously healthy children admitted due to viral bronchiolitis, burns, acute onset seizures, drowning or complications during elective surgical procedures including tonsillectomy and ear ventilation tube placement. Nineteen patients had chronic conditions that included cerebral palsy, chronic seizure disorders, hypoxic ischemic encephalopathy, congenital hydronephrosis, obstructive sleep apnea, cartilage hair dysplasia, bronchiectasis, laryngeal cleft, chromosomal abnormalities, eosinophilic esophagitis, heart transplant, brain stem glioma, Stevens Johnson syndrome, pulmonary nodules and asthma ([S2 Table](#pone.0206305.s002){ref-type="supplementary-material"}). These patients did not have tracheostomy tubes. In addition, eight children had tracheomalacia/laryngomalacia, cough and prematurity.

Due to the retrospective nature of the study the vaccination status of some children is unknown; however, of the children old enough to be vaccinated against pneumococcus 77.7% of the tracheostomy group and 89.5% of the convenience sample were reported as such ([Table 1](#pone.0206305.t001){ref-type="table"} and [S1](#pone.0206305.s001){ref-type="supplementary-material"} and [S2](#pone.0206305.s002){ref-type="supplementary-material"} Tables). The median age of the patients was lower in the convenience sample (2 years, interquartile range 0.9--7) compared with the tracheostomy group (5 years, interquartile range 2--9). One of the patients in the tracheostomy group and three of the patients in the control group were immunocompromised ([S1](#pone.0206305.s001){ref-type="supplementary-material"} and [S2](#pone.0206305.s002){ref-type="supplementary-material"} Tables). There were no statistically significant differences between the patient population in vaccination status, age, sex, immune status, recent antibiotic use and hospitalization ([Table 1](#pone.0206305.t001){ref-type="table"}).

10.1371/journal.pone.0206305.t001

###### Patient characteristics.

![](pone.0206305.t001){#pone.0206305.t001g}

                                      Tracheostomy tube patients (n = 27)   Convenience sample (n = 42)                        P value[^2^](#t001fn002){ref-type="table-fn"}
  ----------------------------------- ------------------------------------- -------------------------------------------------- -----------------------------------------------
  Median Age (interquartile range)    5 (2--9)                              2 (0.9--7)                                         0.99
  Male                                14 (51.9%)                            29 (69.0%)                                         0.24
  Immunocompromised                   1 (3.7%)                              3 (7.1%)                                           0.95
  Antibiotic use last 2 weeks         1 (3.7%)                              1 (2.4%)                                           0.75
  Hospitalization                     15 (55.6%)                            26 (61.9%)                                         0.78
  Reported pneumococcal vaccination   21 (77.7%)                            34[^1^](#t001fn001){ref-type="table-fn"} (86.8%)   0.37

^1^ N = 38 as we excluded 4 patients under 2 months as it is below the recommended age for pneumococcal vaccination.

^2^ Calculated by chi-squared with Yate's correction with the exception of age for which the means were compared using a two-tailed Student's *t* test.

Co-isolation of other potentially pathogenic bacterial species was not significantly different between the groups (63.0% of tracheostomy vs 42.9% of convenience sample isolates P = 0.17) (Tables [2](#pone.0206305.t002){ref-type="table"} and [3](#pone.0206305.t003){ref-type="table"}). Viruses detected are reported ([S1](#pone.0206305.s001){ref-type="supplementary-material"} and [S2](#pone.0206305.s002){ref-type="supplementary-material"} Tables), but as it is difficult in many cases to be certain whether these viruses are the cause of the encounter diagnosis or co-colonizing we did not compare the rates between groups. All immunocompromised patients were co-colonized, with other bacterial species ([S1](#pone.0206305.s001){ref-type="supplementary-material"} and [S2](#pone.0206305.s002){ref-type="supplementary-material"} Tables). The distribution of non-susceptibility to penicillin was not significantly different between the groups (resistant and intermediate, 33.3% of tracheostomy vs 38.1% of convenience sample isolates, P = 0.88).

10.1371/journal.pone.0206305.t002

###### Details of pneumococcal isolates.

![](pone.0206305.t002){#pone.0206305.t002g}

  Isolate                                        Serotype                                   Sequence Type[^3^](#t002fn003){ref-type="table-fn"}   Clonal Complex[^4^](#t002fn004){ref-type="table-fn"}   Penicillin MIC[^5^](#t002fn005){ref-type="table-fn"}   Bacterial Co-colonization[^6^](#t002fn006){ref-type="table-fn"}
  ---------------------------------------------- ------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ -----------------------------------------------------------------
  **Isolates from tracheostomy tube patients**                                                                                                                                                                                                                  
  1                                              19F                                        654                                                   CC654                                                  0.03                                                   \-
  2                                              35B                                        1204                                                  CC558                                                  0.5(I)                                                 *M*.*c*
  3                                              11A/D                                      62                                                    CC63                                                   0.01                                                   *E*., *S*.*a*., *S*.*m*.
  4                                              21                                         432                                                   CC432                                                  0.01                                                   *P*.*a*.
  5                                              15 B/C                                     1757                                                  CC199                                                  0.01                                                   *K*.*p*., *S*.*a*., *S*.*m*.
  6                                              28A                                        546                                                   CC546                                                  0.09                                                   *P*.*a*., *S*.*a*.
  7                                              15 B/C                                     199                                                   CC199                                                  0.04                                                   \-
  8                                              22F/A                                      433                                                   CC433                                                  0.01                                                   *M*.*c*., *P*.*a*.
  9                                              21                                         432                                                   CC432                                                  0.02                                                   *H*.*i*., MRSA
  10                                             35B                                        558                                                   CC558                                                  0.75(I)                                                \-
  11                                             15 B/C                                     199                                                   CC199                                                  \<0.01                                                 *M*.*c*.
  12                                             15 B/C                                     **11360**                                             CC1262                                                 0.04                                                   *C*., *P*.*a*.
  13                                             23B                                        439                                                   CC439                                                  0.04                                                   \-
  14                                             11A/D                                      62                                                    CC63                                                   0.03                                                   *E*., *H*.*i*.
  15                                             23A                                        **12425**                                             CC156                                                  0.25(I)                                                *P*.*a*, *S*.
  16                                             10A                                        816                                                   CC460                                                  0.03                                                   \-
  17                                             NT[^1^](#t002fn001){ref-type="table-fn"}   2315                                                  CC2315                                                 0.19(I)                                                \-
  18                                             15A/F                                      63                                                    CC63                                                   0.25(I)                                                *A*. *M*.*c*. *P*., *P*.*a*., *S*.*d*.
  19                                             9V/A                                       **13967**                                             CC15                                                   0.04                                                   *P*.*a*., *S*.
  20                                             35B                                        558                                                   CC558                                                  1.5(I)                                                 *P*.*a*.
  21                                             23B                                        1373                                                  CC156                                                  0.09                                                   \-
  22                                             19F                                        1203                                                  CC346                                                  2(R)                                                   \-
  23                                             35B                                        3632                                                  CC558                                                  1.5(I)                                                 *E*., *M*.*c*.
  24                                             22F/A                                      7314                                                  CC433                                                  0.04                                                   \-
  25                                             35B                                        558                                                   CC558                                                  0.38(I)                                                *K*.*p*., *S*.
  26                                             6C/D                                       8446                                                  CC156                                                  0.04                                                   MSSA
  27                                             19F                                        425                                                   CC395                                                  0.03                                                   \-
  **Convenience sample**                                                                                                                                                                                                                                        
  1                                              11A/D                                      62                                                    CC63                                                   0.12(I)                                                \-
  2                                              11A/D                                      62                                                    CC63                                                   0.01                                                   \-
  3                                              35B                                        10493                                                 CC558                                                  2(R)                                                   \-
  4                                              6 C/D                                      473                                                   CC473                                                  0.04                                                   \-
  5                                              15 B/C                                     199                                                   CC199                                                  0.02                                                   *M*.*c*.
  6                                              35F/47F                                    1635                                                  CC460                                                  0.06                                                   \-
  7                                              19F                                        320                                                   CC320                                                  4(R)                                                   \-
  8                                              15 B/C                                     **12061**                                             CC156                                                  0.5(I)                                                 \-
  9                                              3                                          13499                                                 CC180                                                  0.03                                                   \-
  10                                             19F                                        654                                                   CC654                                                  0.12(I)                                                *P*.*a*., *R*.
  11                                             19F                                        654                                                   CC654                                                  0.06                                                   MSSA
  12                                             15 B/C                                     3280                                                  CC156                                                  0.19(I)                                                *M*.*c*.
  13                                             6C/D                                       473                                                   CC473                                                  0.03                                                   \-
  14                                             3                                          13499                                                 CC180                                                  0.06                                                   \-
  15                                             19A                                        1451                                                  CC320                                                  4(R)                                                   *M*.*c*.
  16                                             15 B/C                                     199                                                   CC199                                                  0.04                                                   *M*.*c*.
  17                                             19A                                        8748                                                  CC156                                                  0.09                                                   *M*.*c*., MSSA
  18                                             23B                                        439                                                   CC439                                                  0.03                                                   \-
  19                                             16F                                        659                                                   CC659/965                                              0.03                                                   \-
  20                                             11A/D                                      62                                                    CC63                                                   0.04                                                   \-
  21                                             22F/A                                      433                                                   CC433                                                  0.04                                                   \-
  22                                             19F                                        654                                                   CC654                                                  0.04                                                   *H*.*i*, *M*.*c*.
  23                                             6C/D                                       **11413**                                             CC1390                                                 0.04                                                   *N*.*m*., MSSA.
  24                                             16F                                        10439                                                 CC383                                                  0.04                                                   \-
  25                                             38/25F/25A                                 393                                                   CC393                                                  0.04                                                   *H*.*i*.
  26                                             23F                                        36                                                    CC439                                                  0.06                                                   *M*.*c*.
  27                                             11A/D                                      62                                                    CC63                                                   0.03                                                   \-
  28                                             23B                                        1373                                                  CC156                                                  0.12(I)                                                MSSA
  29                                             16F                                        659                                                   CC659/965                                              0.01                                                   \-
  30                                             6C/D                                       1379                                                  CC1379                                                 0.38(I)                                                *H*.*i*.
  31                                             21                                         432                                                   CC432                                                  0.04                                                   \-
  32                                             NT[^2^](#t002fn002){ref-type="table-fn"}   **13966**                                             CC15                                                   0.25(I)                                                \-
  33                                             23B                                        439                                                   CC439                                                  0.04                                                   *H*.*i*.
  34                                             6C/D                                       473                                                   CC473                                                  0.5(I)                                                 *M*.*c*.
  35                                             11A/D                                      62                                                    CC63                                                   0.04                                                   MSSA
  36                                             35B                                        558                                                   CC558                                                  1.5(I)                                                 \-
  37                                             19A                                        1451                                                  CC320                                                  3(R)                                                   \-
  38                                             22F/A                                      433                                                   CC433                                                  0.06                                                   *M*.*c*.
  39                                             19A                                        1451                                                  CC320                                                  3(R)                                                   \-
  40                                             23A                                        338                                                   CC156                                                  0.5(I)                                                 *H*.*i*. MSSA
  41                                             23A                                        338                                                   CC156                                                  0.19(I)                                                \-
  42                                             24 F/A/B                                   162                                                   CC156                                                  0.04                                                   \-

^1^NT *cspA* and *pspK* negative and *aliD* and *aliC* positive.

^2^*cspA*, *pspK*, *aliC* and *aliD* negative confirmed by quelling.

^3^Bold text indicates sequence types novel to this study.

^4^Defined as a group of STs where each strain is a single locus variant of at least one other strain in the group.

^5^Minimum inhibitory concentration; I indicates intermediate levels of penicillin susceptibility and R non-susceptibility to penicillin (9). All other strains are susceptible to penicillin.

^6^Abbreviations for co-colonizing bacterial species: *A*., *Acinetobacter* of unspecified species; *C*. *Corynebacterium* of unspecified species; *E*., *Enterobacter* of unspecified species; *H*.*i*., *Haemophilius influenzae*; *K*.*p*., *Klebsiella pneumonia*; MRSA, methicillin resistant *Staphylococcus aureus*; *M*.*c*., *Moraxella catarrhalis*; *N*.*m*., *Neisseria meningitidis*; *P*., *Proteus* of unspecified species; *Ps*., *Pseudomonas* of unspecified species; *P*.*a*., *Pseudomonas aeruginosa*; *R*., *Rothia* of unspecified species; *S*., *Serratia* of unspecified species; *St*., *Staphylococcus* of unspecified species; *S*.*a*., *Staphylococcus aureus*; *S*.*m*. *Stenotrophomanas maltophila*; Group G *Streptococcus*.

10.1371/journal.pone.0206305.t003

###### Data summary.

![](pone.0206305.t003){#pone.0206305.t003g}

                                                               Strains from tracheostomy tube patients   Strains from convenience sample   P value[^1^](#t003fn001){ref-type="table-fn"}
  ------------------------------------------------------------ ----------------------------------------- --------------------------------- -----------------------------------------------
  Bacterial co-colonization                                    63.0%                                     42.9%                             0.17
  Non-susceptibility to penicillin                             33.3%                                     38.1%                             0.88
  PCV13 coverage                                               14.8%                                     26.2%                             0.41
  Serotypes reported increased post PCV13 (23B, 15 B/C, 35B)   40.7%                                     21.4%                             0.15

^1^ Calculated by chi-squared with Yate's correction.

MLST demonstrated high diversity, but did not support a clonal lineage for strains colonizing children with a tracheostomy. Only 13 of the 40 STs identified represented multiple isolates and six were new STs. The most common STs were ST62 (N = 7), ST199 (N = 4), ST558 (N = 4) and ST654 (N = 4). The 40 STs were members of 23 clonal complexes. The most common of which, CC156 (N = 10), CC63 (N = 8) CC558 (N = 7) and CC199 (N = 5), represented both patient populations.

The 69 strains included 20 serogroups/serotypes. Most of the frequently identified serotypes were common in both groups. The majority of isolates were serotypes not included in PCV13 (85.2% of tracheostomy vs 73.8% of convenience sample isolates, P = 0.41). Although pneumococcal vaccination was not specifically documented, the majority of patients were reported as appropriately vaccinated (77.7% of tracheostomy vs 89.5% of convenience sample P = 0.37). One isolate from each group was non-typeable. One these isolates encoded AliC and AliD \[[@pone.0206305.ref016]\]; while no alternative capsular locus genes were identified in the other.

Discussion {#sec004}
==========

We observed no differences in rates of co-colonization with other potentially pathogenic bacteria between the two groups. We don't believe this was influenced by the distribution of immunocompromised patients. As only 3.7% of the tracheostomy patients and 7.1% of the convenience sample were immunocompromised. A wide range of different co-colonizing bacteria were observed. As co-colonization rates with any specific species or genus were low it was not possible to investigate differences in distribution of individual species between the tracheostomy and control groups.

We observed no significant differences between the isolates from tracheostomy patients and the convenience sample for susceptibility to penicillin or vaccine coverage ([Table 3](#pone.0206305.t003){ref-type="table"}). This observation is important as no studies following introduction of PCV13 have studied pneumococci colonizing the lower airway of paediatric tracheostomy patients. In fact, there have been very few studies of pneumococcal colonization of pediatric patients with a tracheostomy tube. We cannot compare our study with that of Brook *et al*. 1979 as our study was aimed at examining the isolates from tracheostomy patients and not the rates of colonization \[[@pone.0206305.ref005]\]. The study by Adler *et al*. 2012 identified the serotype of isolates; however, they did not differentiate the isolates from adult and pediatric patients \[[@pone.0206305.ref004]\]. The serotypes of the 45 isolates from the trachea or trachea and nasopharynx were 23F, 19F, 17F, 15A, 6A and non-typeable. The limited numbers of serotypes in this study are likely for two reasons. Firstly, patients were sampled between one and three times and it is not clear how many of the isolates were from the same patients and therefore potentially the result of the same colonization event. Secondly, strains were likely spread between patients at this long-term care facility. In contrast, patients included in our study were only at Nationwide Children's for relatively short periods of time prior to sampling. Variation in the serotype distribution as compared to those in our study may reflect differences in vaccination status, which is not discussed, or geographical and temporal patterns of colonization \[[@pone.0206305.ref004]\].

As colonization precedes disease, the serotypes observed can predict those likely to be increasingly observed in disease. Colonization of the lower airways with the non-vaccine serotypes 15B/C, 23B and 35B was noted for the first time. Previous studies have reported post-PCV13 increases in colonization due to non-vaccine serotypes including 23B, 15B/C and 35B \[[@pone.0206305.ref009], [@pone.0206305.ref017], [@pone.0206305.ref018]\]. Our data suggest higher numbers of these serotypes in the tracheostomy patients; although the difference is not significant with the available sample size (40.7% vs 21.4%, [Fig 1](#pone.0206305.g001){ref-type="fig"}, P = 0.15).

![Frequency of emerging serotypes within the tracheostomy and control patient populations.\
The percentage of strains in both patient populations representing serotypes in PCV13, emerging serotypes 15B/C, 23B and 35B, and non-vaccine types is reported. The PCR typing scheme cannot distinguish 9V and 9A. PCV13 includes 9V, but not 9A, hence it is unclear if the isolate classified in this group is a vaccine type and therefore it is reported as a possible vaccine type.](pone.0206305.g001){#pone.0206305.g001}

The increase in colonization and disease due to 35B has been attributed to increased presence of ST588 \[[@pone.0206305.ref010], [@pone.0206305.ref018]\]. Our data also suggest that there is an increase in isolation of single locus variants of ST588 post-PCV13. A previous study suggested ST199 that expressed the 19A capsule and was prevalent in the PCV7 era is now associated with serogroup 15 \[[@pone.0206305.ref010]\]. Our isolates included four ST199 isolates all of which were 15B/C. The pathogenic potential of these isolates is not known, but these data suggest there should be further monitoring of the distribution of these isolates in colonization and disease.

The retrospective nature of the study leads to some limitations including the lack of nasopharyngeal samples, the fact that strains were only isolated at a single time point and that for some patients we did not have confirmed vaccination records. However, this work adds to the current understanding of pneumococci colonizing the airway of children with a tracheostomy. The number of children with a tracheostomy, while increasing, is relatively small and it is possible some of the differences observed in this study would be statistically significant if there were a larger sample size. Despite this, colonization of the lower airways with non-vaccine serotypes 15B/C, 23B and 35B was noted for the first time in patients with tracheostomies and supports recently observed increases in nasopharyngeal colonization and disease due to these serotypes.
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